Search

Displaying results 2041 - 2050 of 10000 in total
  1. Drug

    Elotuzumab

    go.drugbank.com/drugs/DB06317
    ApprovedInvestigational

    Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. … Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb.

  2. Drug

    AZX-100

    go.drugbank.com/drugs/DB06323
    Investigational

  3. Drug

    XmAb 2513

    go.drugbank.com/drugs/DB06324
    Investigational

    XmAb 2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types.

  4. Drug

    Latiglutenase

    go.drugbank.com/drugs/DB06326
    Investigational

  5. Drug

    RG-7795

    go.drugbank.com/drugs/DB06329
    Investigational

  6. Drug

    4-O-Demethylpenclomedine

    go.drugbank.com/drugs/DB06331
    Experimental

    Categories: Heterocyclic Compounds, 1-RingSynonyms: 4-Dmpen, 4-Dm-pen
  7. Drug

    Tucidinostat

    go.drugbank.com/drugs/DB06334
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring
  8. Drug

    Elsiglutide

    go.drugbank.com/drugs/DB06336
    Investigational

  9. Drug

    ARG098

    go.drugbank.com/drugs/DB06338
    Experimental

    ARG098 (anti-Fas IgM monoclonal antibody) was studied in a Phase I clinical trial in 2007 involving patients with rheumatoid arthritis.

  10. Drug

    Coltuximab ravtansine

    go.drugbank.com/drugs/DB06342
    Investigational

    Coltuximab ravtansine (SAR3419) targets CD19 and is being investigated for the treatment of acute lymphoblastic leukemia (ALL).

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors